Onconova Therapeutics' stock price plummeted by more than 70% Monday morning after the company announced disappointing results from late-stage testing of its lead new drug candidate.
Why is Onconova Therapeutics stock on the rise Wednesday?
May 20, 2021 · NEWTOWN, Pa., May 20, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq: ONTX) (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced a one-for-fifteen reverse stock split of its common stock, effective May 20, 2021.
What does the 1-15 reverse split mean for Onconova Therapeutics stock?
Dec 18, 2013 · What: Shares of Onconova Therapeutics ( ONTX -2.44% ), a clinical-stage biopharmaceutical company developing small-molecule drugs to treat cancer, dropped as much as 22% after announcing the...
Is Onconova Therapeutics's PE ratio overvalued or undervalued?
Mar 31, 2022 · Onconova Therapeutics' stock was trading at $5.40 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ONTX shares have decreased by 72.0% and is now trading at $1.51.
Who is the new director of Corporate Development at Onconova?
Feb 20, 2014 · Why Onconova Therapeutics Stock Soared Today. This Week in Biotech: Buyouts, an FDA Approval, and Clinical Data. Oh, My! 3 Horrendous Health-Care Stocks This Week.
Why is onconova Therapeutics stock dropping?
The decrease was primarily related to the Company's focus on its Phase 1 program with narazaciclib, following the completion of the Phase 3 INSPIRE study in 2020. General and administrative expenses were $9.4 million for 2021, compared with $8.3 million for 2020.
Is onconova Therapeutics a good investment?
Is ONCONOVA THERAPEUTICS Stock a good buy in 2022, according to Wall Street analysts? The consensus among 2 Wall Street analysts covering (NASDAQ: ONTX) stock is to Strong Buy ONTX stock.
Will ONTX stock go up?
Stock Price Forecast The 3 analysts offering 12-month price forecasts for Onconova Therapeutics Inc have a median target of 11.00, with a high estimate of 12.00 and a low estimate of 7.00. The median estimate represents a +623.68% increase from the last price of 1.52.
Is onconova stock a buy?
Onconova Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Is ONTX going to reverse split?
Onconova Therapeutics, Inc. (ONTX) will effect a one-for-fifteen (1-15) reverse split of its common stock. The reverse stock split will become effective on Friday, May 21, 2021. In conjunction with the reverse split, the CUSIP number will change to 68232V801.May 20, 2021
Is Onconova Therapeutics a buy right now?
3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Onconova Therapeutics in the last year. There are curren...
How has Onconova Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?
Onconova Therapeutics' stock was trading at $5.40 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World He...
Are investors shorting Onconova Therapeutics?
Onconova Therapeutics saw a decrease in short interest in the month of February. As of February 28th, there was short interest totaling 171,900 sha...
When is Onconova Therapeutics' next earnings date?
Onconova Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, May 16th 2022. View our earnings forecast for On...
How were Onconova Therapeutics' earnings last quarter?
Onconova Therapeutics, Inc. (NASDAQ:ONTX) posted its quarterly earnings data on Thursday, November, 11th. The biopharmaceutical company reported ($...
When did Onconova Therapeutics' stock split? How did Onconova Therapeutics' stock split work?
Onconova Therapeutics's stock reverse split on the morning of Friday, May 21st 2021. The 1-15 reverse split was announced on Thursday, May 20th 202...
What price target have analysts set for ONTX?
3 Wall Street analysts have issued 12 month target prices for Onconova Therapeutics' shares. Their forecasts range from $7.00 to $12.00. On average...
Who are Onconova Therapeutics' key executives?
Onconova Therapeutics' management team includes the following people: Steven M. Fruchtman , President, Chief Executive Officer & Director ( Link...
Who are some of Onconova Therapeutics' key competitors?
Some companies that are related to Onconova Therapeutics include Annexon (ANNX) , scPharmaceuticals (SCPH) , BriaCell Therapeutics (BCTX) , Nex...
What is Onconova Therapeutics?
What: Shares of Onconova Therapeutics ( NASDAQ:ONTX), a clinical-stage biopharmaceutical company developing small-molecule drugs to treat cancer, dropped as much as 22% after announcing the interim results of its late-stage metastatic pancreatic cancer study .
Is Onconova discontinuing Gemzar?
So what: According to Onconova's press release, which came out after the closing bell yesterday, Onconova is discontinuing its late-stage study of intravenous rigosertib in combination with Eli Lilly 's Gemzar in treating front-line metastatic cancer.
About Onconova Therapeutics
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer. The company was founded by Ramesh Kumar and E.
Onconova Therapeutics (NASDAQ:ONTX) Frequently Asked Questions
2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Onconova Therapeutics in the last year. There are currently 2 buy ratings for the stock.
What is Onconova Therapeutics?
Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer.
When is Onconova 2021?
(NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that members of the Company’s management team will participate in A.G.P.’s Virtual Summer Healthcare Symposium on Thursday, June 17, 2021 . The event will consist of 1-on-1 virtual investor meetings. Investors participating in the virtual conference who are
How much was the General and Administrative expenses in 2021?
General and administrative expenses were $2.2 million for the first quarter of 2021, compared with $1.8 million for the first quarter of 2020. The increase was primarily related to higher special stockholder meeting by proxy expenses and insurance costs in the 2021 period.
How much is research and development in 2021?
Research and development expenses were $1.9 million for the first quarter of 2021, compared with $3.4 million for the first quarter of 2020. The decrease was primarily related to lower expenses for the oral rigosertib combination program and the completed Phase 3 INSPIRE study in the 2021 period.
Is Onconova a multi-kinase inhibitor?
Onconova’s novel, proprietary multi-kinase inhibitor ON 123300 is planned to begin a dose-escalation and expansion Phase 1 trial in the U.S. in 2Q21, and a dose-escalation and expansion Phase 1 trial is currently underway in China. Onconova’s product candidate rigosertib is being studied in an investigator-initiated study program, ...
1 ONTX Stock's Price Graph & Average Annual Return
Below is a graph showing closing prices of Onconova Therapeutics Inc (ONTX) for the past 10 years. The below chart uses adjusted close instead of market close prices. (Adjusted close factors in corporate or institutional level actions outside the market.)
2 How Onconova Therapeutics Inc (ONTX) Stock Performed Against The Entire Stock Market
You should not evaluate a stock in isolation. Rather, you will benefit more if you assess the performance against broad indices and similar stocks.
4 10 Biggest One-Day Losses
Let us now see 10 biggest one-day losses of Onconova Therapeutics Inc (ONTX) stock.
Conclusion
Hopefully, the above report helps you learn about the past ten-year performance of Onconova Therapeutics Inc (ONTX) shares. Kindly use the sections below to suggest corrections or improvements to the report.
Want to become a smart investor?
Netcials reports section helps you with deep insights into the performance of various assets over the years. We are constantly upgrading and updating our reports section. Feel free to access them. Do not forget to leave your feedback.
How much is Onconova Therapeutics stock worth in 2021?
The Onconova Therapeutics stock price gained 2.14% on the last trading day (Friday, 9th Jul 2021), rising from $6.07 to $6.20. , and has now gained 3 days in a row. It will be exciting to see whether it manages to continue gaining or take a minor break for the next few days. During the day the stock fluctuated 4.33% from a day low at $6.00 to a day high of $6.26. The price has fallen in 7 of the last 10 days and is down by -16.55% for this period. Volume fell on the last day by -90 thousand shares and in total, 234 thousand shares were bought and sold for approximately $1.45 million. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.
Does Onconova Therapeutics gain volume?
Onconova Therapeutics gained volume on the last day, but on falling prices. In technical terms, this is called divergence and may be an early warning. In some cases, increasing volume on falling prices may be considered positive, but that is mainly in typical "sell-offs".
How many shares of Onconova Therapeutics have changed hands?
As of this writing, more than 245 million shares of the stock have changed hands. To put that in perspective, the company’s daily average trading volume is about 39 million shares. Onconova Therapeutics is a biopharmaceutical company with a focus on developing new treatments for cancer.
Where is Onconova Therapeutics located?
It operates out of its headquarters in Pennsylvania.
